Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high risk rhabdomyosarcoma (RMS 2005): a multicentre, open label, randomized phase 3 trial.

Bisogno G, De Salvo GL, Bergeron C, Gallego S, Merks JHM, Kelsey A, Martelli H, Minard-Colin V, Orbach D, Glosli H, Chisholm J, Casanova M, Zanetti I, Devalck C, Ben Arush M, Mudry P, Ferman S, Jenney M, Ferrari A. Lancet Oncol. 2019 Sept 24. https://doi.org/S1470-2045(19)30617-5.